Actively Recruiting
Better Experiences in Substance Treatment: A Brief Alcohol-Focused Intervention Tailored for Patients in Opioid Agonist Treatment
Led by University of Notre Dame · Updated on 2026-01-15
60
Participants Needed
1
Research Sites
12 weeks
Total Duration
On this page
Sponsors
U
University of Notre Dame
Lead Sponsor
N
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are studying a brief alcohol-focused intervention designed specifically for patients who are receiving prescribed buprenorphine for opioid use disorder and who currently drink alcohol. The study aims to see if this tailored intervention is practical and acceptable, and whether it can improve alcohol-related outcomes. This initial proof-of-concept study will help decide if a larger clinical trial should be done in the future. Participants will be randomly assigned to one of two groups. One group will receive their usual opioid treatment with prescribed buprenorphine and any related behavioral support for medication adherence and relapse prevention. The other group will receive a brief opioid-informed alcohol intervention based on motivational enhancement therapy and cognitive behavioral therapy, delivered in weekly in-person sessions over four weeks. The intervention is tailored to the needs of patients in opioid treatment. During the study, researchers will assess how acceptable and feasible the intervention is by the end of the four-week period. Participants will be monitored for alcohol use and related outcomes. The study involves weekly sessions for those in the intervention group, and all participants will continue their regular treatment. The total study duration for each participant is four weeks, at which point the main outcomes will be evaluated.
CONDITIONS
Brief Title
Better Experiences in Substance Treatment: A Brief Alcohol-focused Intervention Tailored for Patients in Opioid Agonist Treatment
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants must be taking prescribed buprenorphine for at least 2 weeks
- Participants must be 18 years or older
- Meet DSM-5 criteria for alcohol use disorder (AUD)
- Participants must report alcohol use 2 1 day/week on average in the past 28 days
- Participants must be able to read simple English
You will not qualify if you...
- Currently receiving formal alcohol use treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 4 weeks
Participants attend weekly in-person behavioral therapy sessions tailored to their needs while receiving opioid agonist treatment.
Weekly visits for 4 weeks
Trial Site Locations
Total: 1 location
1
The University of Notre Dame
Notre Dame, Indiana, United States, 46556
Actively Recruiting
Research Team
R
Ryan Carpenter, PhD
B
Beth A Arnold, M.S.
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here